ClearBridge Mid Cap Trails in Q1 as AI Fears Hit Health Care

Overview

• ClearBridge’s Q1 Mid Cap letter reports the strategy trailed its benchmark even as the Russell Midcap Index rose 1.3%.
• The firm says IT, health care and consumer discretionary bets weighed on returns, with health names hit by fears that AI could upend drug research and digital ads.
• In response, the team sold its stake in contract research firm ICON and kept a small holding in Doximity, saying the platform could benefit from AI over time.
• The manager also called out Churchill Downs, noting pressure from possible approvals for rival casinos and concern about new online prediction markets that could pull bettors away.
• The letter describes a quarter where mid caps gained ground as large caps fell 4.2% and small caps rose 0.9%, and it reiterates a focus on adaptable consumer brands.